Nimesulida Generis (Nimesulide)

Nimesulide works by reversibly inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the synthesis of prostaglandins that drive inflammation, pain and fever. By sparing COX‑1 activity, it aims to maintain gastric protection while delivering anti‑inflammatory effects.

The appropriate dose of Nimesulida Generis is set by the prescribing clinician based on the patient’s age, weight, severity of symptoms and overall health status. Dosage adjustments may be required for renal or hepatic impairment, and the prescriber will follow local regulatory guidelines.

Safety data for nimesulide in pregnancy and lactation are limited. Because of potential risks to the fetus and infant, the drug is generally avoided unless the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Nimesulida Generis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimesulida Generis is a COX‑2 selective NSAID, offering analgesic and anti‑inflammatory effects similar to other agents such as ibuprofen or diclofenac but with a lower impact on COX‑1 mediated gastric protection. However, it carries a distinct risk profile, notably for liver toxicity, which may influence the choice of therapy.

Store Nimesulida Generis at room temperature, ideally below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Nimesulida Generis is administered orally. The tablets (or other oral dosage form) should be swallowed whole with a glass of water, preferably after a meal to reduce the chance of gastrointestinal irritation, unless the prescriber advises otherwise.

The most serious risks include hepatotoxicity, which may present as jaundice or elevated liver enzymes, severe skin reactions such as Stevens‑Johnson syndrome, gastrointestinal ulceration or bleeding, and acute renal impairment. Patients should seek immediate medical attention if they notice signs of liver injury, rash, or unexplained abdominal pain.

Nimesulida Generis should be avoided in individuals with known hypersensitivity to nimesulide, other NSAIDs, or sulfonamide compounds. It is also contraindicated in patients with active peptic ulcer disease, severe hepatic or renal impairment, and in those taking certain anticoagulants without close medical supervision.